Focus: Wockhardt is a specialty pharma company headquartered in Parsippany, NJ, focused on specialty dermatology and generic medications with a heavily concentrated revenue base. The company operates primarily in the post-exclusivity generic space with minimal pipeline innovation activity.
Profile data last refreshed 11h ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow Wockhardt to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Core revenue driver (95% of total) but post-loss-of-exclusivity; faces generic competition and formulary pressure.
Help build intelligence for Wockhardt
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Wockhardt's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Mature generic antibiotic with minimal revenue contribution.
Specialty injectable for rare/serious indications; very low revenue base.
Mature injectable antibiotic with minimal market presence.
Generic respiratory agent; revenue not disclosed.
Generic ACE inhibitor; low-value commodity product.
Generic antipsychotic with QT risk; restricted use limits market.
64 discontinued, 4 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo+18 more products